Advertisement

FDA Approves Albiglutide for Type 2 Diabetes — Physician’s First Watch

Medical News |
April 16, 2014

FDA Approves Albiglutide for Type 2 Diabetes

By Kristin J. Kelley

The FDA has approved albiglutide (marketed as Tanzeum), a glucagon-like peptide-1 (GLP-1) receptor agonist, for use along with diet and exercise to treat adults with type 2 diabetes.

The weekly injectable will carry a warning about thyroid C-cell tumors seen in rodent studies with other GLP-1-receptor agonists. The drug should not be used in patients with a history of medullary thyroid carcinoma (MTC); the FDA is requiring the manufacturer to conduct a postmarketing study to identify increases in MTC incidence. Additional studies will examine the drug's safety and efficacy in pediatric patients and in those at high cardiovascular risk.

Albiglutide improved glycemic control in some 2000 patients who participated in eight clinical trials. Common side effects included diarrhea, injection site reactions, and nausea.

Reader Comments (1)

PhD pharmacology Other Healthcare Professional, Pharmacology/Pharmacy, Tripoli Libya

it was very interesting to read hope to see more developments

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement